Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14901494 | 0.91 | RARB (0.51) | PLA2G4BKDM4EMAPK1TDP1CASR | |
| SCHEMBL14901491 | 0.88 | PLA2G4B (0.46) | PLA2G4BKDM4EMAPK1TDP1CASR | |
| SCHEMBL14901489 | 0.87 | PLA2G4B (0.57) | PLA2G4BKDM4EMAPK1TDP1LMNA | |
| SCHEMBL12267321 | 0.87 | HTT (0.54) | PLA2G4BKDM4EMAPK1TDP1CASR | |
| SCHEMBL14901479 | 0.84 | POLB (0.55) | PLA2G4BLTA4HKDM4ELMNAPOLB | |
| SCHEMBL17563457 | 0.82 | PLA2G4B (0.54) | PLA2G4BKDM4EMAPK1TDP1CASR | |
| Febuprol SCHEMBL1229179 | 0.82 | PLA2G4B (0.57) | PLA2G4BLTA4HKDM4EMAPK1TDP1 | |
| SCHEMBL7171686 | 0.81 | PLA2G4B (0.60) | PLA2G4BKDM4EMAPK1TDP1CASR | |
| SCHEMBL10965245 | 0.81 | PLA2G4B (0.52) | PLA2G4BKDM4EMAPK1TDP1CASR | |
| SCHEMBL12267195 | 0.80 | HTT (0.50) | PLA2G4BKDM4EMAPK1TDP1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109758-A1 | BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | SHBG, KLK3, HSD17B11 | PLA2G4B 804/4885LTA4H 2660/4885KDM4E 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.